BESPONSA 1MG INF.COZ.HAZ.KULL.KONS.TOZ

BESPONSA (inotuzumab ozogamicin) is a medication used in the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), a type of cancer affecting the blood and bone marrow. Mechanism of Action: BESPONSA is a monoclonal antibody-drug conjugate that targets CD22, a protein found on the surface of leukemia cells. The medication consists of an antibody that binds to CD22, linked to a cytotoxic agent called calicheamicin. Once BESPONSA binds to CD22 on leukemia cells, it is internalized into the cell, where calicheamicin is released. Calicheamicin then binds to DNA, causing breaks in the DNA strands and leading to cell death. Benefits: The benefits of BESPONSA include:

• Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults.
• Improvement in overall response rates and survival outcomes compared to standard treatments in clinical trials.
• Potential for increased rates of complete remission and minimal residual disease negativity.

Dosage and Administration: BESPONSA is administered by intravenous infusion. The recommended dosage and administration schedule may vary depending on factors such as the patient’s weight, medical history, and treatment response. Healthcare professionals typically determine the appropriate dose and infusion schedule. Suitability: BESPONSA is indicated for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Its suitability for an individual patient is determined based on factors such as disease status, prior treatments received, overall health status, and any underlying medical conditions. Availability and Pricing: BESPONSA is available by prescription only and is typically administered in medical facilities equipped to perform intravenous infusions, such as hospitals or specialized clinics. Pricing can vary between countries and regions, and specific pricing information would need to be obtained from pharmaceutical databases, local pharmacies, or healthcare providers. BESPONSA represents an important treatment option for individuals with relapsed or refractory acute lymphoblastic leukemia, offering significant improvement in response rates and survival outcomes. However, like all medications, it may cause side effects, and patients should be closely monitored by healthcare professionals during treatment.